Key Points
- Martine Rothblatt sold 9,500 shares of United Therapeutics on March 6 at an average price of $477.67 for proceeds of $4.54 million, leaving her with just 130 shares (a 98.65% reduction).
- United Therapeutics beat EPS estimates with $7.70 vs. $6.78 expected and reported a 41.9% net margin and 7.4% revenue growth, although revenue ($790.2M) slightly missed consensus ($814.8M).
- Institutional and analyst sentiment is largely positive: major investors (e.g., Wellington) significantly increased stakes, several banks raised price targets, and the stock holds a "Moderate Buy" consensus with an average target near $539.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $477.67, for a total transaction of $4,537,865.00. Following the completion of the sale, the chief executive officer directly owned 130 shares in the company, valued at approximately $62,097.10. This represents a 98.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
United Therapeutics Stock Up 1.3%
UTHR opened at $535.81 on Wednesday. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $548.12. The company's 50-day moving average price is $483.83 and its two-hundred day moving average price is $457.40. The stock has a market cap of $23.48 billion, a price-to-earnings ratio of 19.20, a PEG ratio of 1.91 and a beta of 0.84.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million for the quarter, compared to analysts' expectations of $814.80 million. During the same quarter in the previous year, the firm posted $6.19 EPS. United Therapeutics's revenue was up 7.4% on a year-over-year basis. As a group, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Institutional Investors Weigh In On United Therapeutics
Several institutional investors have recently bought and sold shares of UTHR. Wellington Management Group LLP boosted its stake in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. Darwin Global Management Ltd. bought a new stake in United Therapeutics in the 3rd quarter worth $317,617,000. Norges Bank purchased a new stake in shares of United Therapeutics during the fourth quarter worth about $293,418,000. Invesco Ltd. grew its stake in shares of United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company's stock worth $254,219,000 after purchasing an additional 419,588 shares during the last quarter. Finally, Avoro Capital Advisors LLC increased its holdings in United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock valued at $1,269,803,000 after purchasing an additional 383,838 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research analysts have recently weighed in on the company. Royal Bank Of Canada increased their price target on United Therapeutics from $587.00 to $643.00 and gave the stock an "outperform" rating in a research note on Thursday, February 26th. TD Cowen upped their price objective on shares of United Therapeutics from $525.00 to $575.00 and gave the company a "buy" rating in a report on Wednesday, February 25th. Bank of America reiterated a "neutral" rating on shares of United Therapeutics in a research report on Wednesday, February 25th. UBS Group lifted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a "buy" rating in a research note on Thursday, March 5th. Finally, Wells Fargo & Company boosted their price target on shares of United Therapeutics from $423.00 to $466.00 and gave the company an "equal weight" rating in a research report on Thursday, February 26th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $539.00.
View Our Latest Research Report on UTHR
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
